發(fā)布時間：2018-01-05 16:34

  本文關鍵詞：趨化因子受體CXCR6及其配體CXCL16在膀胱尿路上皮癌中的表達及其臨床意義　出處：《川北醫(yī)學院》2015年碩士論文　論文類型：學位論文

  更多相關文章： 膀胱尿路上皮癌 趨化因子受體CXCR6 趨化因子CXCL16 免疫組織化學 單因素生存分析

【摘要】：目的:觀察趨化因子受體CXCR6及其配體CXCL16在膀胱尿路上皮癌和正常膀胱粘膜組織中的表達情況,并分析其與腫瘤臨床生物學行為以及復發(fā)和進展的關系。為進一步深入研究CXCR6/CXCL16影響膀胱尿路上皮癌生物學行為的機制提供線索。材料和方法:選擇89例初診為膀胱尿路上皮癌組織的標本,30例正常膀胱粘膜組織:腫瘤標本中非肌層浸潤性膀胱尿路上皮癌64例,肌層浸潤性癌25例;低級別尿路上皮癌32例,高級別癌57例;單發(fā)腫瘤48例,多發(fā)41例;非肌層浸潤性膀胱尿路上皮癌中,隨訪期間出現(xiàn)術后首次復發(fā)38例,未復發(fā)26例;出現(xiàn)術后首次進展22例,未進展42例。采用ElivisonTM免疫組織化學方法,檢測膀胱尿路上皮癌組織、正常膀胱粘膜組織中趨化因子受體CXCR6及其配體CXCL16的表達情況。并結合患者的臨床病理因素以及非肌層浸潤性膀胱癌患者的預后情況進行分析。運用SPSS13.0軟件進行統(tǒng)計學分析,趨化因子受體CXCR6及其配體CXCL16表達水平的分析采用X2檢驗,膀胱尿路上皮癌中CXCR6/CXCL16表達的相關性分析采用Spearman等級相關。采用Kaplan-Meier方法計算非肌層浸潤性膀胱癌患者的無復發(fā)生存率和無進展生存率,繪制生存曲線并進行Log-Rank檢驗。以P0.05為差異有統(tǒng)計學意義。結果： 1.正常膀胱粘膜組織中趨化因子受體CXCR6蛋白的表達水平為:20%(6/30),腫瘤組織中為:75.3%(67/89);正常膀胱粘膜組織中趨化因子CXCL16蛋白的表達水平為10%(3/30),腫瘤組織為73%(65/89);組間比較差異均有統(tǒng)計學意義(P0.001、P0.001)。趨化因子受體CXCR6及其配體CXCL16蛋白在膀胱尿路上皮癌中的表達成正相關(r=0.747、P=0.000*0.001)。2.低級別和高級別膀胱尿路上皮癌中趨化因子受體CXCR6陽性表達水平分別為56%(18/32),86%(49/57),組間比較差異有統(tǒng)計學意義(P0.05)。非肌層浸潤性膀胱癌術后復發(fā)組與未復發(fā)組趨化因子受體CXCR6蛋白的表達水平分別為84%(32/38)和46%(12/26),組間差異有統(tǒng)計學意義(P0.05);術后進展組與未進展組中趨化因子受體CXCR6蛋白的表達水平分別為91%(20/22)、57%(24/42),差異有統(tǒng)計學意義(P0.01)。膀胱尿路上皮癌組織中趨化因子CXCL16蛋白表達與患者的性別、年齡、腫瘤大小、腫瘤數(shù)目、腫瘤的臨床分期、病理級別均無關。且非肌層浸潤性膀胱尿路上皮癌的術后復組與未復發(fā)組、術后進展組與未進展組比較,趨化因子CXCL16蛋白的表達表達水平均無明顯差異(P0.05、P0.05)。3.Kaplan-Meier曲線和Log-Rank檢驗顯示,非肌層浸潤性膀胱尿路上皮癌患者趨化因子受體CXCR6陽性表達組和CXCR6陰性組術后無復發(fā)生存率相比較,組間差異有統(tǒng)計學意義(P0.05)。趨化因子受體CXCR6陽性表達組和陰性表達組術后無進展生存率比較,差異有統(tǒng)計學意義(P0.01)。趨化因子受體CXCR6陽性表達組的無復發(fā)生存率和無進展生存率均低于陰性組。而趨化因子CXCL16的表達情況不影響非肌層浸潤性膀胱尿路上皮癌患者的術后無復發(fā)生存率和無進展生存率。(P0.05、P0.05)結論:趨化因子受體CXCR6及其配體CXCL16在膀胱尿路上皮癌中的表達水平高于正常膀胱粘膜組織。趨化因子受體CXCR6在膀胱尿路上皮癌中的表達情況與其病理級別和臨床分期成正相關,并且可能影響非肌層浸潤性膀胱癌患者的預后。提示CXCR6/CXCL16生物學軸可能參與了膀胱尿路上皮癌的發(fā)生、發(fā)展,并可能影響患者的預后。
[Abstract]:Objective: To observe the expression of chemokine receptor CXCR6 and its ligand CXCL16 in bladder urothelial carcinoma and normal bladder mucosa tissues, and analyze its relationship with clinical and biological behavior of the tumor recurrence and progression. Provide clues for further research on the mechanism of bladder CXCR6/CXCL16 affects the biological behavior of epithelial carcinoma. Materials and methods: 89 cases of newly diagnosed bladder urothelial carcinoma specimens, 30 cases of normal bladder mucosa: tumor specimens of non muscle invasive urothelial carcinoma of the bladder in 64 cases, muscle invasive carcinoma in 25 cases; low grade urothelial carcinoma in 32 cases, 57 cases of high grade carcinoma; 48 cases of solitary tumor multiple, 41 cases; non muscle invasive urothelial carcinoma of the bladder, the first postoperative recurrence occurred in 38 cases during the follow-up period, no recurrence in 26 cases; 22 cases of the first progress after operation, no progress in 42 cases by ElivisonTM immunohistochemical method, Detection of bladder urothelial carcinoma. The expression of chemokine receptor CXCR6 and its ligand CXCL16 in normal bladder mucosa tissue. Combined with clinical pathological factors in patients with non muscle invasive bladder cancer patients prognosis were analyzed. Statistical analysis was performed using SPSS13.0 software, the chemokine receptor CXCR6 and its ligand CXCL16 expression the level of analysis using X2 test, correlation analysis between the expression of CXCR6/CXCL16 in bladder urothelial carcinoma using Spearman rank correlation. Using Kaplan-Meier method to calculate the non muscle invasive bladder cancer patients without recurrence and progression free survival, survival curve and Log-Rank test in P0.05. The difference was statistically significant. Results: 1. normal bladder tissue expression of chemokine receptor CXCR6 protein was 20% (6/30), tumor tissue was 75.3% (67/89); normal bladder Bladder mucosa in expression of chemokine CXCL16 protein 10% (3/30), the tumor tissue was 73% (65/89); there were significant differences among the groups (P0.001, P0.001). The expression of chemokine receptor CXCR6 and its ligand CXCL16 protein in bladder urothelial carcinoma was positively correlated (r=0.747, P=0.000*0.001) chemokine receptor CXCR6 expression levels were 56%.2. low grade and high grade bladder urothelial carcinoma (18/32), 86% (49/57), there were significant differences between the groups (P0.05). Non muscle invasive bladder cancer recurrence group and non recurrence group expression level factor receptor CXCR6 protein were 84% (32/38) and 46% (12/26), there was significant difference between the groups (P0.05); after the operation in group and non progressive group in the expression of chemokine receptor CXCR6 protein were 91% (20/22), 57% (24/42), the difference was statistically significant (P0.01) wings. CXCL16 gene protein expression and patient's sex, age, tumor size, tumor number, more bladder urothelial carcinoma, tumor clinical staging, pathological grade were unrelated. And non muscle invasive bladder cancer postoperative rehabilitation group and non recurrence group, comparison group and no postoperative progress in the control group, there were no significant difference between the expression of chemokine CXCL16 expression (P0.05, P0.05).3.Kaplan-Meier curve and Log-Rank test showed that non muscle invasive bladder cancer patients tend to relapse free survival compared with receptors of CXCR6 positive group and CXCR6 negative group, the two groups had statistical significance the difference between (P0.05). Chemokine receptor CXCR6 positive expression group and negative group postoperative progression free survival rate comparison, the difference was statistically significant (P0.01). Chemokine receptor CXCR6 positive expression of the relapse free survival and progression free The survival rate was lower than the negative group. The expression of chemokines CXCL16 does not affect the non muscle invasive bladder cancer patients had no recurrence and progression free survival (P0.05, P0.05). Conclusion: the expression of chemokine receptor CXCR6 and its ligand CXCL16 in bladder urothelial carcinoma higher than that in the normal bladder mucosa. The expression of chemokines and pathological grades and clinical chemokine receptor CXCR6 in bladder urothelial carcinoma staging was positively correlated, and may affect non muscle invasive bladder cancer prognosis. CXCR6/CXCL16 biological axis may be involved in bladder urothelial cancer occurrence, development. And may affect the prognosis of patients.

【學位授予單位】：川北醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R737.14

【參考文獻】

相關期刊論文 前3條

1 ;Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma[J];癌癥;2011年05期

2 程浩;陳念永;;趨化因子受體CXCR6在乳腺癌細胞系中的表達及其意義[J];四川大學學報(醫(yī)學版);2014年03期

3 方業(yè)穎;雷倩倩;李燕;陳念永;;非分泌型CXCL16在乳腺癌細胞系中的表達及對其生物學特性的影響[J];四川大學學報(醫(yī)學版);2013年04期

，

本文編號：1383952